

Special Issue

Cancer Biomarker Research and Personalized Medicine 2.0

Message from the Guest Editors

Treating individual patients based on specific factors, such as biomarkers, is what differentiates personalized medicine from standard treatment regimens. Although personalized medicine can be applied to almost any branch of medicine, it is perhaps most easily applied to the field of oncology. Cancer is a heterogeneous disease. Through biomarkers, patients could be separated into cohorts with respect to distinctions in disease predisposition, prognosis, and expected response rates to different treatments. There is currently a major drive in oncology to achieve personalized cancer medicine through the identification and use of disease-specific biomarkers. These biomarkers include genes, intracellular or secreted proteins, circulating tumor cells, exosomes, and DNA. This Special Issue aims to describe current developments in biomarker research ranging from in vitro and animal model studies, through to preclinical and clinical validation trails. In doing so, we will describe exciting new tissue- and blood/urine-based biomarker research, highlighting the advantages and potential limitations of incorporating biomarkers into clinical practices.

Guest Editors

Dr. James Meehan


The Royal (Dick) School of Veterinary Studies, Roslin Institute, The University of Edinburgh, Edinburgh, Midlothian, Scotland, UK

Dr. Mark E. Gray

The Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, Midlothian, Scotland, UK

Deadline for manuscript submissions

closed (1 March 2024)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/109634

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

[jpm](https://mdpi.com/journal/)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

[jpm](https://jpm.mdpi.com)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).